News & Updates

A new oral COVID-19 antiviral therapy comprising nirmatrelvir and ritonavir substantially slashes the risk of hospitalization or death compared with placebo in nonhospitalized adults with COVID-19 who are at high risk of developing severe illness, according to final analysis of the EPIC-HR* study.

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

Initial treatment with intravenous immunoglobulin (IVIG) plus infliximab resulted in less additional therapy in multisystem inflammatory syndrome in children (MIS-C) compared with IVIG alone, according to a recent study.

Among competitive and recreational swimmers, women and older people are at higher risk of having swimming-induced pulmonary oedema (SIPE), according to a study from Sweden.